SAP S/4HANA Public Cloud for Life Sciences: Opportunity for Regulated Companies in D-A-CH

The life sciences industry in Germany, Austria and Switzerland is under intense pressure from both innovation and regulation: new therapeutic approaches such as Cell & Gene, increasing M&A activity, global supply chains, stricter GxP requirements and growing cyber risks. At the same time, many companies are still running ERP systems that have not seen a major upgrade in years, which in turn directly impacts usability, security and, consequently, the ability to innovate.
This is precisely where SAP S/4HANA Public Cloud for Life Sciences comes in, as it offers pharma, MedTech and biotech companies a way to combine modern cloud ERP functionality, GxP compliance and AI innovations, without multi-year large-scale projects and with clearly plannable OPEX costs. Consulting firms such as DHC help ensure that this transformation in regulated environments is carried out securely and with proper technical safeguards.

Why SAP S/4HANA Public Cloud for Life Sciences Is Becoming Increasingly Important in the DACH Region

Life sciences companies in the DACH region are increasingly looking for cloud options that take regulatory requirements seriously while enabling innovation. Key advantages can be derived from current SAP initiatives and customer programs:

• Faster Innovation Instead of 10-Year Upgrades
  Rather than carrying out a major on-premise upgrade every five to ten years, SAP S/4HANA Public Cloud delivers new functions on a continuous basis, including AI innovations. This is why it is particularly relevant for companies that are still working with outdated SAP interfaces because no upgrade has been performed in years and modern features are only available to a limited extent.
• Relief for IT Security and Operations
  The cybersecurity threat landscape is increasing dramatically, while many mid-sized life sciences companies in Germany, Austria and Switzerland can barely maintain the required security level in their own data centers. This is exactly where the Public Cloud comes in: SAP takes over key aspects of operations, security, monitoring and patching, and this is a real advantage, especially for research-oriented organizations and companies without large IT departments.
• Flexible Cost Model: From CAPEX to OPEX
  With SAP Public Cloud, large one-time investments (CAPEX) can be converted into ongoing operating costs (OPEX). For high-growth pharma startups, biotech companies or smaller MedTech firms in the DACH region, this model is often significantly more attractive.
• Two-Tier Scenarios for Growing Corporate Groups
  Headquarters often remain on SAP S/4HANA Private Cloud or on-premise, while new acquisitions, subsidiaries or production sites are connected via S/4HANA Cloud, Public Edition. This allows life sciences groups to integrate M&A activities faster without having to put every unit through a three-year transformation project.

Where SAP S/4HANA Public Cloud Makes Sense in Life Sciences Today

Currently, SAP S/4HANA Public Cloud is particularly well suited for areas where GxP (GMP/GCP/GDP) is not yet the primary focus, such as:

• Finance & Controlling
• selected service processes
• standard procurement processes (SD/Procurement) outside of strictly regulated areas
• R&D-related scenarios without direct GxP relevance

Especially in these areas, life sciences companies in the DACH region can already benefit from a modern cloud ERP platform today and simultaneously gain experience with release cycles, test automation and cloud governance.

SAP Roadmap: GxP Enablement by 2028

For GxP-critical core processes, particularly in production and quality assurance, SAP is working on a structured roadmap:

• Development of a signature service on the SAP Business Technology Platform (BTP)
• GxP-compliant change logging and audit trails
• GxP-oriented cloud operations models (release changes, test windows, incident handling, documented processes, training in data center operations)

SAP’s goal is to gradually make GxP-relevant applications available in the SAP S/4HANA Cloud, Public Edition starting from 2027/2028:

• Early “quick wins”: Cell & Gene use cases, procurement scenarios and specific life sciences solutions
• Subsequently, more heavily regulated processes in QM and Manufacturing, with go-lives expected from summer 2028

For pharma, MedTech and biotech companies in the DACH region, this means: start now with non-GxP-critical scenarios and align your own IT and CSV strategy so that the upcoming GxP cloud functionalities can be leveraged in time.

GxP Validation in the SAP Public Cloud: A New Mindset Instead of Mammoth Upgrades

Many managers in quality, IT and CSV are asking:
“How am I supposed to validate a system that is continuously changing?”
The traditional approach of “a major upgrade every five years that ties up resources for two years” no longer works in the Public Cloud, because the system evolves continuously. Instead, the focus shifts to:

• Continuous Release Assessment
  With tools such as the Digital Discovery Assessment, the Release Navigator and release overviews, companies can identify which scope items are affected and which changes are potentially GxP-relevant.
• Risk-Based Release Assessment
  Not every change in SAP S/4HANA Public Cloud requires a full (re-)validation. What matters is a clear methodology for distinguishing between security-relevant patches, technical changes and genuine process innovations.
• Establishing Lean Test and Documentation Processes
  Instead of infrequent large-scale projects, the goal is repeatable, efficient processes for continuous validation, supported by test automation, standard templates and ideally AI-assisted evaluations.

This is precisely where DHC brings its combined expertise in SAP S/4HANA, Computer System Validation (CSV) and life sciences regulation. The goal is to ensure a secure transition from traditional on-premise validation approaches to cloud- and release-driven CSV models.

GxP Consortium & Co-Innovation: Life Sciences Are Helping Shape the SAP Public Cloud

To address the requirements of pharma, MedTech and biotech at an early stage, SAP has established a GxP consortium. Customers and partners from around the world participate, including well-known companies from Germany as well as other life sciences companies from Europe, the USA and Asia.
In this context, customers provide feedback on:

• E-signature strategies and signature services
• functional gaps in GxP-relevant processes
• expectations regarding documentation, operations and audit readiness

New “frontrunner” customers can get involved through simple feedback agreements. Collaboration typically takes place:

• in quarterly consortium meetings,
• supplemented by monthly coordination with pilot customers.

For implementation partners like DHC, participation in these formats is important to actively contribute requirements from the DACH region and to prepare customers early for the future state of SAP S/4HANA Public Cloud.

Sovereign Cloud: When Life Sciences Have Particularly Sensitive Data

Beyond GxP, topics such as data sovereignty and geopolitical risks are also coming into sharper focus. The SAP Sovereign Cloud addresses customers with particularly high requirements for data storage, access security and regional compliance, for example:

• Companies with overlaps to healthcare/hospitals
• Manufacturers of dual-use components in the MedTech sector
• Producers of vaccines or components with a security-relevant context

SAP is investing heavily in regional cloud infrastructures and software environments, including in Europe. For life sciences companies in the EU, this can be relevant when:

• data must be stored exclusively in the EU (EU-only)
• the individuals who access data or operate systems must be based within a specific region or country
• additional security and sovereignty requirements must be met

Especially in combination with GxP, data protection and export control requirements, the Sovereign Cloud option is becoming a strategic topic for certain life sciences segments.

How DHC supports Life Sciences Companies in the DACH Region with SAP S/4HANA Public Cloud

As a specialized consulting firm for SAP, compliance and digitalization in regulated industries, DHC accompanies pharma, MedTech and biotech companies in the DACH region across the entire lifecycle of cloud ERP initiatives:

• Strategy & Roadmap
  Development of cloud and S/4HANA roadmaps, evaluation of public cloud scenarios, two-tier architectures and Sovereign Cloud options.
• Implementation of SAP S/4HANA Cloud, Public Edition
  Process design, template development and rollout in non-GxP-critical areas, including preparation for future GxP extensions.
• Computer System Validation (CSV) & GxP Compliance
  Establishing risk-based cloud validation approaches, designing release and test processes and supporting audits.
• Managed Services & Continuous Improvement

ongoing management of SAP S/4HANA environments, adaptation to new SAP releases and integration of AI-powered tools, e.g. for test and documentation support.

Conclusion: Set the Course Now for SAP S/4HANA Public Cloud in Life Sciences

The coming years will bring multiple waves simultaneously in life sciences IT:
cloud ERP, AI, GxP enablement of the SAP Public Cloud and Sovereign Cloud scenarios.

Those who miss these waves will be tied to outdated structures for the next ten years. For life sciences companies in Germany, Austria and Switzerland, this means in concrete terms:

• start now with non-GxP-critical scenarios in SAP S/4HANA Public Cloud
• define an integrated cloud, GxP and CSV strategy early on
• actively incorporate the SAP roadmap through 2028 into your own planning
• participate in shaping future GxP functionalities through consortia and pilot projects

DHC stands by your side as a partner, combining SAP S/4HANA expertise, life sciences process knowledge and deep know-how in GxP compliance and Computer System Validation.